Anti-Cd19/Cd22 Car Nk Cells
Refractory B-Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.Cell therapyEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Refractory B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Linperlisib The First Affiliated Hospital of Xiamen University | Phase 2 | CCC |
psb202 Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Phase 1 | CC |
Anti-Cd19 Icar Nk Cells Allife Medical Science and Technology Co., Ltd. | Early Phase 1 | C |
Anti-Cd22 Car Nk Cells Allife Medical Science and Technology Co., Ltd. | Early Phase 1 | C |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →